According to Data Bridge Market Research new Market report “Global Injectable Drug Delivery Market, By Type (Devices (Conventional Injection Devices, Self Injection Devices), Formulations (Conventional Drug Delivery, Noble Drug Delivery, Long Acting Injection Formulations), By Applications (Autoimmune Diseases, Hormonal Disorders, Orphan Diseases, Oncology, Others), By Usage Pattern (Curative Care, Immunizations, Other Usage Patterns), By Mode of Administration (Skin, Circulatory, Organs, Central Nervous System), By End User (Hospitals, Clinics, Home Care Settings, Research Laboratories, Pharma & Biotech Companies), By Geography (North America, Europe, Asia-Pacific, South America, Rest of the World) – Trends and Forecast to 2022”, has accounted value of USD 343.2 billion in 2015 and is expected to reach USD 797.2 billion by 2022, growing at a CAGR of 12.7%.
Report Access: https://www.databridgemarketresearch.com/reports/global-injectable-drug-delivery-market
Injectable drug delivery is a promising alternative for drugs that are ineffective when administered orally. It is widely accepted due to advantages such as quick reactions and high ef ficacy. Injectables are considered to be the second-most-used drug delivery systems, subsequent to oral medicines. Therefore, the injectable drug delivery market continues to be an attractive, high-margin segment with huge potential.
Improving patient acceptability, demand for biologics in the pharmaceutical market, rising prevalence of chronic diseases like cancer and diabetes, increasing access to care, technological advancements and product innovation, and increase in demand for self-injectors are the major factors propelling the growth of the market. The growth of the injectable drug delivery market is also driven by generic injectables. On the other hand, needlestick injuries and infections, development of other drug delivery methods, quality of formulations, and slower approval processes are the major factors restraining the growth of the injectable drug delivery market.
According to the Australian Institute of Health and Welfare, in 2011, chronic diseases were the leading cause of illness, disability, and death in Australia and it accounted for 90% of all deaths. Similarly, in 2012, according to the European Commission, chronic diseases in Europe account for 86% of all deaths. In the European Union, an estimated USD 778.06 billion is spent per year on treating chronic diseases. Many of these chronic diseases require frequent medical aid.
Around 86% of the healthcare costs in the U.S. are for treating people with chronic diseases. This increase in prevalence of chronic diseases can be attributed to unhealthy lifestyles, including excess consumption of alcohol and tobacco. The above-mentioned factors also increase health risks such as obesity, high blood pressure, and cholesterol, which in turn contribute towards the unprecedented rise in cases of chronic diseases.
Diabetes and cancer are deemed to be the greatest threats, especially to populations in the BRICS (Brazil, Russia, India, China and South Africa) countries. In 2012, cancer and diabetes were the major therapeutic areas where injectable drug delivery technologies were used, having accounted for 20.5% and 39.7% of the market share, respectively.
Biologics are considered to be the fastest-growing segment of the pharmaceutical industry. Biologics are large molecules that need to be administered by injections given their size and profile. As single -use wearable or bolus injectors deliver precise amounts of the drug in doses as high as 30mL, they are considered as invaluable. This surge in the biologics market can be attributed to the rise in the number of chronic diseases such as blood diseases, cancer and related conditions, diabetes, cardiovascular diseases, and autoimmune diseases.
The key products in the injectable drug delivery market are Humira (AbbVie Inc.), which is used for the treatment of moderate to severe rheumatoid arthritis (RA). Enbrel (Pfizer) is a prescription medicine that can be self-injected and is used for the treatment of long-term inflammatory diseases. Herceptin (Roche) is a subcutaneous injection used for the treatment of cancer.
Market Segmentation:
Injectable drug delivery is mainly dependent formulations and devices. Formulation developments can reduce the frequency of intake of drugs, reduce the volume needed for each administration, and decrease side effects such as immunogenicity. Drug delivery device developments such as microneedles or autoinjectors are easy to self-administer and improve patient compliance. The injectable drug delivery market is segmented on the basis of therapeutic applications, usage patterns, modes of administration, and end users. In 2016, the market is dominated by the formulation segment with 76.3% market share and is also expected to grow at the highest CAGR of 12.2% in the forecasted period 2016 to 2022.
Devices include conventional injection devices and self-injection devices. The Self Injection devices are further segmented into needle free injector devices, wearable injector devices, pen injector devices and autoinjector devices. This segment is expected to drive the market growing at the highest CAGR of 21.3% in the forecast period. The self injection devices is dominated by needle free injector devices with 48.3% market share in 2016, growing at a CAGR of 22.7% in the forecast period. By product the needle free injectors is further segmented into fillable needle-free injectors and prefilled needle-free injectors. On the basis of technology, the needle-free injectors market is further segmented into jet-based needlefree injectors, spring-based needle-free injectors, laser-powered needle-free injectors, and vibration-based needle-free injectors. By usability the needle free injector is segmented into disposable and reusable injectors. By product the autoinjectors is further segmented into fillable needle-free injectors and prefilled needle-free injectors. On the basis of technology, the autoinjectors market is further segmented manual and automated autoinjectors. By design the autoinjectors is segmented into standardized and customizable autoinjectors. The pen injectors market is further classified based on basis on number of cartridges into single chamber and dual chamber pen injectors. By design the pen injectors market is segmented into standardized and customizable pen injectors. The conventional drug delivery market is segmented based on material into glass and metal, based on product into fillable and prefilled, and by usability into disposable and reusable conventional injection devices.
Formulations are segmented into conventional drug delivery, novel drug delivery, and long-acting injection formulations. The novel drug delivery formulations segment is expected to dominate the drug delivery formulation market in 2016 with 43.1% market share, and growing at the highest CAGR of 13.4% in the forecast period 2016 to 2022. Conventional drug delivery formulations market is further segmented into solutions, reconstituted formulations, suspensions and emulsions. Novel drug delivery formulations market is further segmented based on product type into colloidal dispersions and microparticles. Colloidal dispersions include products such as niosomes, liposomes, polymeric mixed micelles and nanoparticles. The nanoparticles sub segment is categorized into three type’s solid lipid nanoparticles, nanosuspensions and nanoemusions. The microparticles segment is segmented into two types microcapsules and microspheres.
On the basis of applications the global Injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others. In 2016, the hormonal disorders applications segment is expected to dominate the market with 43.1% market share. The autoimmune diseases segment is further sub segmented based on indications into rheumatoid arthritis, multiple sclerosis, crohns disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others. The report also includes disease burden, prevalence data of all indications mentioned above. Some of the other applications included in the report are allergies, pain management, hepatitis C, aesthetic treatments and hemophilia.
On the basis of usage pattern the global injectable drug delivery market is segmented into curative care, immunization and, others. In 2016, the curative care is expected to dominate the market with 93.2% market share and is expected to grow at a CAGR of 13.1% in the forecast period.
Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system. Administration through skin is the most common and the highest growing segment with 13.7% CAGR in the forecast period 2016 to 2022.
On the basis of end user the global Injectable drug delivery market is segmented into hospitals, clinics, home care settings, research laboratories and, pharma & biotech companies. Among these, in 2016 hospitals dominate the market and the trend is expected to remain the same till 2022.
Geographical Segmentation
Based on geography the market is segmented into 5 geographical regions, North America, Europe, Asia-Pacific, South America and rest of the world. The geographical regions are further segmented into 24 major countries such as U.S. Canada, Mexico, Germany, France, U.K., Belgium, Switzerland, Belgium, Turkey, Japan, China, Singapore, Brazil, India, Russia, South Africa and many others. In 2015, North America is expected to account for the largest share of 47.3% of this market. Increasing prevalence of chronic diseases such as heart disease, stroke, cancer, diabetes, obesity, and arthritis contribute to the rising demand for injectables in North America. According to the National Health Council, it is estimated that by 2020, the number people getting affected with chronic diseases will reach around 157 million, with 81 million affected with multiple conditions. According to Centers for Disease Control and Prevention (CDC), in 2012, 47% of the U.S. adults suffered from at least one of the major risk factors for heart disease or stroke. The rising prevalence of chronic diseases is increasing the demand for new technologies for their treatment. The Country Health Advice (U.S.) recommends vaccination for travelers every 6 months; this is expected to have a positive impact on the market growth.
Asia Pacific is expected to register the highest CAGR of 14.2% during the forecast period. The high growth in this market can be attributed to the growing incidences of chronic diseases like diabetes, cardiovascular diseases, and auto-immune diseases. According to the International Diabetes Federation (IDF), in 2011, South East Asia accounted for one-fifth of the diabetic population in the world; India accounted for 86% of the total diabetic population in this region. The injectable drug delivery market in countries like India, China, and Japan is expected to witness significant growth in the coming years. To leverage the growth opportunities in this region, many major companies are focusing on investing in Asian countries. For instance, in July 2014, West Pharmaceutical Services, Inc. (U.S.) opened its first facility in India. This expansion helped the company in increasing its customer base and in meeting the rising demand for injectable drugs in the Asia region.
Competitive Landscape:
The Injectable drug delivery market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. Some examples of recent strategies/developments are: In April, 2015 Pfizer, Inc. acquired Fragmin (injectable product) from Eisai Inc., a privately owned pharmaceutical company based in Tokyo, Japan, In May, 2015 Eli Lilly and Company and Sanford-Burnham Medical Research Institute (U.S.) announced their collaboration plans for the development of immunological therapies focusing on lupus, Sjögren's syndrome, inflammatory bowel disease, and other autoimmune disorders; among many other developments. The report includes market shares of cord stem cell banking market for global, Europe, North America, Asia Pacific and Rest of the World.
Some of the major players operating in the global Injectable drug delivery market are Baxter International, Inc., Becton Dickinson and Company, Gerresheimer AG, Pfizer, Inc., Schott AG, Alkermes Plc., Eli Lilly and Company, Sandoz, Terumo Corporation, Teva Pharmaceuticals Industries Ltd. among others.
Browse Related Reports:
Asia Pacific (APAC) Pen Needles Market, By Product Type (Standard Pen Needles, Safety Pen Needles), By Product Length (Nano Length, Medium Length, Long length), By Usability (Reusable Pen Needles, Disposable Pen Needles), By Application (Diabetes, Growth Hormone Deficiency, Others), By Therapy (Insulin, Glucagon-like peptide-1, Growth Hormones), By End-User (Hospitals, Clinics, OTC, Home Healthcare, Others), By Country (China, India, Japan, South Korea, Singapore, Australia, Rest of APAC) – Trends and Forecast to 2022
Europe Drug Delivery Devices Market, By Route of Administration (Oral (Solid, Liquid, Semi-Solid), Injectable, Topical, Pulmonary (MDI, DPI, Nebulizers), Nasal, Ocular, Implantable, Transmucosal), By End-User (Hospitals, Ambulatory Surgery Centers/Clinics, Home Care Settings, Diagnostic Centers, Others), By Country (Germany, France, U.K., Spain, Italy, Russia, Netherlands, Turkey, Belgium, Switzerland, Rest of Europe) – Trends and Forecast to 2022
Contact:
Data Bridge Market Research
4th Floor, Mega Center,
Magarpatta City, Pune – 411028
Tel: +1-888-387-2818
Email: Sales@databridgemarketresearch.com
Visit Data Bridge Blog@ https://www.databridgemarketresearch.com/blog/
